Name: Enliven Therapeutics, Inc. (ELVN) Financial Statements
Creator: FinSpry

Enliven Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Enliven Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	80.78	64.57	31.02	38.44	32.15
Selling, General & Administrative	23.78	18.96	7.77	13.00	9.54
Operating Expenses	104.55	83.53	38.79	51.44	41.70
Operating Income	-104.55	-83.53	-38.79	-51.44	-41.70
Other Income/Expense
Interest Income	14.89	11.97	1.13	0.02	0.03
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	0.87	0.02	-34.90	0.18	0.15
Income
Income Before Tax	-88.79	-71.58	-37.66	-51.38	-41.36
Income Tax Expense	0.23	0.00	0.09	0.00	0.00
Net Income	-89.02	-71.58	-37.66	-51.38	-41.36
Net Income - Continuous Operations	-89.02	-71.58	-37.66	-24.74	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-104.24	-71.29	-38.58	-51.13	-41.14
EBIT	-104.55	-71.58	-38.79	-51.38	-41.36
Depreciation & Amortization	0.32	0.30	0.22	0.10	0.10
Earnings Per Share
Basic EPS	-2.00	-2.00	-1.00	-9.00	-14.00
Diluted EPS	-2.00	-2.00	-1.00	-9.00	-14.00
Basic Shares Outstanding	47.07	35.55	41.10	5.42	3.48
Diluted Shares Outstanding	47.07	35.55	41.10	7.81	3.48